# Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
> **Food and Drug Administration** · Notice of availability. · Published 2016-06-10 · 81 FR 37500
## Document
- **Document number:** 2016-13798
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 81 FR 37500
- **Publication date:** 2016-06-10
- **HHS docket:** Docket No. FDA-2015-D-3539
## Abstract

The Food and Drug Administration (FDA or the Agency) is announcing the availability of a guidance for industry entitled "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act." The guidance describes FDA's interim regulatory policy regarding outsourcing facilities that compound human drug products using bulk drug substances while FDA develops the list of bulk drug substances that can be used in compounding under the Federal Food, Drug, and Cosmetic Act (the FD&C Act).

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2016/06/10/2016-13798/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503b-of-the-federal-food-drug)
---
*AI Analytics · CC0 1.0*